Efficacy and Safety of Zingiber Officinale Roscoe Extract on Body Fat

A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Zingiber Officinale Roscoe Extract on Body Fat

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03260751

Enrollment

Registered

2017-08-24

Start date

2017-02-03

Completion date

2018-01-29

Last updated

2019-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

This study was conducted to investigate the effects of daily supplementation of Zingiber officinale Roscoe extract on body fat.

Detailed description

This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. Forty subjects were randomly divided into Zingiber officinale Roscoe extract 200 mg or placebo group. The investigators measured Body Fat Mass, Percent Body Fat, Fat Free Mass, weight, and body mass index.

Interventions

DIETARY_SUPPLEMENTZingiber officinale Roscoe extract 200 mg

2 cap/day, 800 mg/cap for 12 weeks

DIETARY_SUPPLEMENTPlacebo

Placebo for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* age between 19 and 65 years, * BMI 25\ 29.9 kg/m2 * subjects giving written informed consent

Exclusion criteria

* Significant variation in weight(more 10%) in the past 3 months * Cardiovascular disease, e.g. arrhythmia, heart failure, myocardial infarction, and patient with pacemaker * History of disease that could interfere with the test products or impede their absorption, such as gastrointestinal disease or gastrointestinal surgery * Participation in any other clinical trials within past 2 months * Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * Pregnancy or breast feeding etc,.

Design outcomes

Primary

Measure	Time frame	Description
Changes of body fat mass	Baseline and 12 week	Body fat mass was measured in study baseline and 12 week

Secondary

Measure	Time frame	Description
Changes of fat free mass	Baseline and 12 week	Fat Free Mass was measured in study baseline and 12 week
Changes of weight	Baseline and 12 week	Weight was measured in study baseline and 12 week
Changes of body mass index	Baseline and 12 week	Body mass index was measured in study baseline and 12 week
Changes of percent body fat	Baseline and 12 week	Percent body fat was measured in study baseline and 12 week

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026